New research depicts that a specific intestinal bacterium called Bifidobacterium infantis EVC001 (B. infantis) impacts the immune system development in infants and could lower the risk of allergic and autoimmune diseases later in life. The study was conducted on 208 infants at the Karolinska University Hospital in Sweden. The objective was to evaluate the developmental changes in the immune system with bifidobacterial species and various microbes expressing the human milk oligosaccharides (HMO) utilization genes. Furthermore, a second cohort study was conducted on 40 breastfed infants in California to further assess the benefits of HMO utilization gene expressing microbes.
Half the group received B. infantis EVC001, which possesses all HMO utilization genes, whereas the other didn’t receive any supplements. The study found the presence of B. infantis EVC001 strain early in an infant’s…
